than 20% have long-term survival. 1,2 Because chemotherapy dose-intensity has been shown to correlate strongly with response and progression-free survival in metastatic A single institutional pilot study was conducted in which 12 poor-risk neuroblastoma (NB) patients were uni-NB, 3 many centers are currently treating poor-risk patients with consolidation regimens that include myeloablative formly treated with multi-agent induction chemotherapy followed by myeloablative consolidation chemochemotherapy or chemoradiotherapy followed by allogeneic bone marrow transplant (BMT) or autologous BMT. therapy and unpurged peripheral blood stem cell (PBSC) rescue. In addition to using standard criteria While the efficacy of myeloablative vs nonmyeloablative consolidation therapy has not been determined, some of the for evaluating response to induction chemotherapy, tumor cell contamination of the peripheral blood and/or best long-term survival rates have been reported with highdose myeloablative chemotherapy with or without totalbone marrow was analyzed in seven patients by immunocytology using a panel of five anti-NB monobody irradiation, and bone marrow rescue. 2,4-8 However, the ability to provide bone marrow stem cells for patient clonal antibodies. Seven patients had morphologic evidence of bone marrow disease at the time of diagnosis, rescue following intensive therapy can be limited by marrow contamination with tumor cells, and by the lack of and two additional patients had tumor cells detected in bone marrow samples by immunocytology prior to the adequate marrow reserves to harvest sufficient numbers of stem cells. second cycle of chemotherapy. After three cycles of chemotherapy, two of the 12 patients continued to have
nine patients to determine the incidence of tumor contamitherapy. An additional three cycles of chemotherapy, identical to the first three cycles, were administered to patients nation. Our studies demonstrate that neuroblasts are no longer detected in the bone marrow and peripheral blood with responsive tumors. Patients were re-evaluated after the sixth cycle of chemoin a subset of patients after three cycles of chemotherapy. Furthermore, there was no evidence of tumor contamination therapy, and second-look surgery was performed on all patients who had responsive tumors and no morphological in PBSC harvests collected at this time.
evidence of bone marrow disease. In the operating room an effort was made to remove all residual tumor. If resection was not possible, multiple biopsies of the tumor were Materials and methods performed. After recovery from surgery, patients received myeloablative therapy consisting of thiotepa 300 mg/m 2 i.v. Patients daily, day −7 to day −5, and cyclophosphamide 1500 From December 1991 to September 1994, 11 newly diagmg/m 2 i.v. daily, day −5 to day −2. On day 0, the PBSCs nosed consecutive patients older than 1 year of age with were infused. Due to inadequate yields of PBSCs, one International Neuroblastoma Staging System (INSS) stage patient (patient 3) received a supplement of stem cells 4 NB 20, 21 were enrolled on a pilot study conducted at Chilobtained from bone marrow harvest. Thirty to 40 days foldren's Memorial Hospital in Chicago designed to treat lowing the PBSC infusion, seven of the 11 patients received poor-risk NB. In addition, one child with recurrent NB was 2400 cGy to the primary tumor bed in 20 fractions over enrolled on the study. This child was initially diagnosed 10 days. with INSS stage 4 NB at 2. years of age, and relapsed in Routine supportive care included hospitalization in the blood and bone marrow 3 years following an allogeneic rooms with positive pressure undirectional airflow systems, bone marrow transplant. The protocol was approved by the prophylactic acyclovir 250 mg/m 2 /dose i.v. twice daily, Children's Memorial Institutional Review Board and writdaily fluconazole 50-200 mg p.o., gammaglobulin 250 ten informed consent was obtained for each patient. Diagmg/kg i.v. weekly for the first 100 days and then monthly nosis was made according to international criteria, 20, 21 and for 3 months, pentamidine 4 mg/kg i.v. monthly from day was based on unequivocal pathologic examination of tumor +35-40 to +180, and broad spectrum antibiotics for treattissue or bone marrow and urine catecholamine excretion. ment of febrile neutropenia. All patients received GM-CSF Clinical data collected included age at diagnosis, sex of 1000 g/m 2 i.v. daily, until they achieved an ANC the child, and stage of disease according to the INSS and Ͼ1000 × 10 9 /l. Computed tomography scans, bone scans, outcome. Tumor extent at diagnosis was determined by and urine catecholamine assays were performed at +30 and computed tomography, bone scan, meta-iodobenzylguani-+100 days to determine disease status. dine (MIBG) scan, and bone marrow aspirate. Nine patients were simultaneously enrolled on the Pediatric Oncology Peripheral blood stem cell collection Group (POG) NB Biology Study No. 9047, and prior to treatment, tumor N-myc copy number was analyzed by Bone marrow aspirates were performed prior to each cycle Southern blot or fluorescence in situ hybridization at the of chemotherapy until two sequential bone marrow samples POG reference laboratory at St Jude Children's Research were morphologically free of tumor. Twenty-four hours folHospital using standard methods. [22] [23] [24] Tumor tissues from lowing completion of each chemotherapy cycle all patients patients 2 and 10 were not available at the time of diagreceived daily G-CSF to enhance stem cell mobilization. nosis. However, N-myc copy number was measured in PBSCs were collected approximately 7 to 10 days followrecurrent tumor by Southern blot analysis in the laboratory ing completion of a chemotherapy cycle, once the periphof one of the authors (SCL). One patient (3) did not have eral white blood cell count recovered to 0.8-1.0 × 10 9 /l. tumor tissue available for N-myc analysis. The response to
The harvest was performed through a double lumen cuffed induction chemotherapy was determined according to intercentral venous line (Hickman or Broviac, Salt Lake City, national criteria after cycles 3 and 6 using bone scan, com-UT, USA), and 1.5 to 2.0 blood volumes were processed puted tomography, bone marrow aspirate, and urine cateither on a CS-3000 (Baxter, Deerfield, IL, USA) or Cobe echolamine metabolite determination. Following cycle 6, a Spectra pheresis machine (Cobe, Denver, CO, USA). The second MIBG scan was performed.
pheresis was repeated on 2 to 4 consecutive days after cycles 4, 5 and 6 of induction chemotherapy until a minimum of 0.9 × 10 8 mononuclear cells/kg were collected. The Treatment duration of each pheresis was approximately 4. h.
All patients were initially treated with three cycles of comCell processing and analysis bination chemotherapy delivered every 21 days. The chemotherapy cycle was delayed 1 week if the absolute Samples from the individual daily harvests were obtained for total cell count, CD34 + content, hematopoietic progenineutrophil count (ANC) was Ͻ250 × 10 6 /l or if the platelet count was Ͻ30 000 × 10 9 /l. G-CSF (5-10 g/kg/day) was tor assay, and bacterial culture; the PBSC harvests were suspended in a final dimethyl-sulfoxide (DMSO) concenstarted 24 h after each cycle of chemotherapy was completed to mobilize stem cells, and it was continued until the tration of 10%. Each PBSC harvest was cryopreserved individually in a controlled rate freezer to −70°C, and stored patient achieved an ANC of Ͼ1000 × 10 6 /l. Patients were evaluated for response after the third cycle of chemoin a liquid nitrogen tank until the time of PBSC rescue as previously described. 10 Cells expressing surface antigen Results CD34 were identified by flow cytometry analysis using fluoroscein isothiocyanate (FITC)-conjugated mouse antiPatients and response to therapy CD34 monoclonal antibody (Becton Dickinson, San Jose,
The clinical characteristics of the 12 high-risk NB patients CA, USA). In addition, surface antigen expression of enrolled on this pilot protocol are shown in Table 1 . Eleven CD33, CD38, and HLA-DR was determined using FITCchildren had newly diagnosed stage 4 disease, and one conjugated mouse anti-CD33, anti-CD38, and anti-HLApatient had recurrrent NB. All 12 patients were older than DR antibodies (Becton Dickinson, San Jose, CA, USA).
1 year of age at the time they were enrolled on study, and Hematopoietic progenitors (colony-forming cells (CFU)-seven of the 12 children had N-myc amplified tumors. mix, erythroid burst-forming cells (BFU-E) and colony-forSeven patients had morphologic evidence of bone marrow ming units granulocyte-monocyte (CFU-GM) were assayed disease at the time of diagnosis (Table 2) . However, using in a methylcellulose system containing phytohemagglutimore sensitive immunocytologic methods, tumor cells were nin-stimulated leukocyte conditioned medium and erythrodetected in bone marrow samples from two additional poietin using a kit from Stem Cell Technologies patients prior to the second cycle of chemotherapy (patients (Vancouver, Canada). On days 7 and 14, hematopoietic 5 and 7). progenitor colony number was determined.
Of the five patients who did not have morphologic evidence of bone marrow disease at the time of diagnosis, two patients (3 and 8) were classified as stage 4 because of extensive disease in the chest and abdomen. Patient 2 had a large retroperitoneal primary tumor and lung nodules which Immunocytologic analysis were determined to be tumor metastases pathologically. Patient 5 had a primary adrenal mass with metastases to The immunocytologic analysis was performed in the labthe thoracic cavity, inguinal and cervical lymph nodes, and oratory of one of the authors (TJM). Bone marrow and peribone. In addition to disease in the retroperitoneum and pheral blood samples from seven patients were obtained mediastinum, patient 7 had metastatic disease in suprabefore cycles 2 and 4 of induction chemotherapy to evaluclavicular lymph nodes. ate whether contaminating neuroblasts were present. In
The chemotherapy schema is shown in Table 3 . All 12 addition, samples from 29 PBSC harvests collected from patients achieved a partial response (PR) after the first three nine patients were analyzed for tumor contamination.
cycles of chemotherapy, and the bone marrow was morphoUnfortunately, patient 1 was enrolled on this protocol prior logically tumor-free in all but one patient (patient 11). to the time arrangements were made to examine the Sequential immunocytologic analysis of peripheral blood samples for tumor contamination, and initially only PBSC and bone marrow samples from seven patients during the samples were collected for immunocytology. Patients 11 induction phase of chemotherapy demonstrated that five and 12 did not have PBSC samples analyzed because the patients had tumor-free peripheral blood and bone marrow immunocytology laboratory was closed during the period samples prior to the 4th cycle of chemotherapy, while two of time the samples were collected. patients continued to have detectable bone marrow disease Mononuclear cell fractions were isolated from each sam- (Table 2) . Patient 11 had both morphologic and immunople by density gradient separation on Ficol-Hypaque logic evidence of bone marrow disease after five cycles of (Pharmacia, Uppsala, Sweden), tested for cell viability by chemotherapy, and was removed from our study. The Trypan Blue (Sigma Chemical Co, St Louis, MO, USA), remaining 11 patients completed the induction chemoand resuspended in Liebovitz L15 medium (GIBCO, Long therapy and underwent 'second-look' surgery. Following Island, NY, USA) supplemented with 15% fetal bovine completion of induction therapy, three patients were serum (GIBCO) at a cell volume of 6.0 × 10 6 cells/ml as determined to be in a complete response (CR), five had a described. 19 The cell suspension was incubated at room very good partial response (VGPR), and three had a partial temperature for 45 min with a cocktail of antibodies generresponse (PR) ( Table 1 ). All 11 received myeloablative chemotherapy followed by PBSC rescue (Table 4) . ously provided by Dr John Kemshead (UJ13A, 5.1. H11, M340, UJ127.11, and anti-Thy 1). Cells were then spun onto glass slides using a Shandon cytocentrifuge (Shandon, Peripheral stem cell collection and rescue Philadelphia, PA, USA), and stored overnight at 4°C. Slides were fixed in a paraformaldehyde solution at 4°C for 30
The 11 patients underwent a total of 50 pheresis. Two to min, washed in phosphate-buffered saline, and then placed four phereses were completed following each cycle of on a Biotek automated immunostainer (Biotek, Walkerville, chemotherapy in an out-patient setting. The procedure was MD, USA) and incubated with Biotek immunoreagents for well tolerated. No patient developed hypocalcemia or citalkaline phosphatase staining as described. 19 Positive conrate toxicity. However, one patient did become hypotensive trol slides were prepared with cells from the neuroblastoma during the pheresis, and required fluid administration. Most cell line HTB-10. Non-immune mouse serum at 5 g/ml patients developed thrombocytopenia and received platelet was used as a negative control. If control studies did not transfusions. The total number of phereses performed for yield the expected result, the assays were repeated with a each patient was two to nine (mean 4.5) ( Table 5 ). Three fresh cocktail of antibodies. A minimum of 2 × 10 6 cells patients underwent their first harvest 8 to 10 weeks following diagnosis; seven patients had their first harvest perforper sample were examined. med at week 11 to 13 after diagnosis, and one patient range 0-685) respectively. The mononuclear cell dose/kg collected in each apheresis ranged from 0.1 × 10 8 to underwent initial PBSC harvest at week 15. Ten patients had additional aphereses performed following cycle 5 of 1.5 × 10 8 (Table 5 ). No significant difference in cell yields was observed after the different cycles of chemotherapy. chemotherapy, 2 to 5 weeks after the first harvest. Four patients also had PBSCs collected after cycle 6 of chemo-
The median percentage of CD34 + cells in each apheresis ranged from 0.2 to 3.5% (0.1 × 10 6 to 2.2 × 10 6 CD34 + therapy (weeks 13 to 19 following diagnosis). Hematopoietic progenitor colony number was detercells/kg). Twenty-nine PBSC harvests collected from nine patients were analyzed by immunocytology for the presmined on each harvest for quality control. In each experiment 0.5 × 10 6 mononuclear cells were plated. On day 7 ence of contaminating tumor cells, and all samples were determined to be negative (Table 2) . Mononuclear cell the mean CFU-GM was 70.5 (median 28; range 0-586), and the mean BFU-E count was 15.6 (median 5; range 0-dose/kg infused ranged from 0.9 × 10 8 to 5.9 × 10 8 with a median 2.0 × 10 8 mononuclear cells/kg (Table 6 ). Patient 3 135). On day 14 the mean CFU-CM and BFU-E counts were 200 (median 139; range 0-879) and 106 (median 52; received 1.5 × 10 8 /kg bone marrow stem cells in addition Although peripheral blood stem cells have been harvested from adult cancer patients and used for hematopoietic reconstitution following myeloablative therapy for several to 0.5 × 10 8 /kg PBSCs. The median time to absolute neutrophil count of Ͼ500 × 10 6 /l was 14 days (range 9-33 days), years, only recently have stem cells been successfully harvested from the peripheral blood of children weighing less and platelet count recovery (Ͼ20 × 10 9 /l) was observed at a median of 27 days (range 11-64 days). than 20 kg. We report our experience with intensive multiagent induction chemotherapy followed by myeloablation and peripheral blood stem cell rescue in 12 poor-risk NB Toxicity and patient outcome patients. Eleven of the 12 patients achieved cytologic bone marrow remissions with the multi-agent induction chemoFive patients had documented bacteremia and two patients developed fungal infections following the PBSC rescue, therapy, and received myeloablative chemotherapy followed by PBSC rescue. These 11 patients underwent PBSC prior to hematopoietic recovery. One patient developed a urinary tract infection. Additional transplant-related morharvesting without complication, and in all but one case at least 0.9 × 10 8 mononuclear cells/kg were collected from bidity included cardiac insufficiency which resolved (one patient), and mild skin sloughing which healed without PBSC harvests. The cell yields are similar to that reported in other pediatric series. 15, 16 There was no transplant-related complication (one patient). There was no transplantrelated mortality. mortality, although seven episodes of bacteremia or fungal infection were documented following PBSC infusion. At day +100, all 11 patients were alive without evidence of progressive disease (Table 1) . Six were determined to Engraftment of neutrophils and platelets was observed after a median of 14 and 27 days, respectively, which is similar be in CR, one had a VGPR, and four had a PR. The first three patients enrolled in the study developed recurrent disto what has been observed in adult clinical trials and the few published pediatric studies. [9] [10] [11] [12] [13] [14] [15] [16] ease at their primary tumor site 9 to 17 months following completion of therapy. Recurrent metastatic disease was In addition to using the standard international criteria for evaluating response to the induction chemotherapy, we also also observed in one of these three patients. The fourth patient relapsed in her bone marrow 15 months following analyzed samples of peripheral blood and bone marrow from seven patients sequentially during therapy using sensi-PBSC rescue, and was not further evaluated to determine if there were additional sites of recurrent disease per the tive immunocytologic methods to determine if tumor cells were present. 18, 19 Although NB cells from individual request of his family. Post-relapse, two patients received no further therapy. The other two patients were treated on patients were not tested for reaction with the antibodies used in our studies, Moss and colleagues 25 have previously phase I or II studies (Table 1 ). All four patients died of disease 9 to 19 months following diagnosis.
demonstrated that virtually all NB cells react with this cocktail of antibodies. These studies demonstrated that In an effort to decrease the high rate of local failure, the next seven patients enrolled on the study were treated with tumor cells were not detected by morphology or immunocytology in the bone marrow or peripheral blood of five of radiation to the site of their primary disease approximately 30 to 40 days after the PBSC rescue, once they achieved the seven patients analyzed following three cycles of intensive multi-agent chemotherapy. Furthermore, our study an ANC Ͼ1000 × 10 6 /l and a platelet count of Ͼ25 000 × 10 9 /l. The four patients who were in PR at day +100 indicates that 'tumor-free' PBSC harvests can be collected after four cycles of conventional chemotherapy, as all 29 (patients 6, 7, 8 and 9) received additional therapy following completion of the treatment outlined in the pilot study of the PBSC harvests we analyzed by immunocytology showed no evidence of tumor contamination. Unfortuas shown in Table 1. nately, for logistical reasons, the PBSC harvests from some lowing myeloablative therapy. In a subset of patients, tumor cells are no longer detected morphologically or by immunoof the patients were not analyzed by immunocytology.
It is possible that a small number of neuroblasts may cytology in the peripheral blood or bone marrow after three cycles of conventional chemotherapy. Immunocytologic have been present in the PBSC harvests which were not detected by immunocytology. Others have shown that analysis of PBSC grafts harvested at this time demonstrate no evidence of tumor contamination. While the number of clonogenic neuroblastoma tumor cells can be present in peripheral blood samples that are negative by immunopatients in our cohort is small, the outcome appears to be better than the historical results at this institution when, cytology. 25 It is also possible that more sensitive assays such as analysis of tyrosine hydroxylase expression using similar to other centers, less than 15% of our poor-risk patients survived 2 years with conventional doses of the reverse-transcription polymerase chain reaction 17 may have demonstrated minimal residual disease. However, chemotherapy. However, the high incidence of relapse seen in this and other studies emphasizes the urgent need for the even when minimal residual disease was measured by other methods, other investigators have reported similar results.
development of more effective therapy. We are currently conducting another pilot study for poor-risk NB patients in Using the sensitive reverse-transcription polymerase chain reaction assay, Miyajima and colleagues 17 sequentially which the consolidation phase of therapy consists of three repetitive PBSC rescues following cycles of very high-dose examined both peripheral blood and bone marrow samples for neuroblast contamination in 15 patients with stage IV multi-agent chemotherapy. Early results suggest that this approach is feasible, and that most of the treatment can disease. These investigators observed that after several cycles of conventional chemotherapy, a subset of these be given in an outpatient setting. Further follow-up will determine if intensifying therapy in this manner will lead poor-risk patients cleared their bone marrow and peripheral blood of tumor cells. Interestingly, at the time of PBSC to improved long-term survival for children with poorrisk NB. harvesting, these investigators demonstrated that the incidence of tyrosine hydroxylase mRNA positivity was significantly lower in PBSC samples than in bone marrow samples obtained concurrently, suggesting that tumor cell
